Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
For 260 pneumococcal and 266 staphylococcal strains, ranbezolid MICs ranged from < or =0.06 to 4 micro g/ml. The MICs for pneumococci were similar irrespective of the strains' beta-lactam, macrolide, or quinolone susceptibilities, and ranbezolid MICs for coagulase-negative staphylococci were lower than those for Staphylococcus aureus. Ranbezolid was bacteriostatic against pneumococci. Ranbezolid MICs were similar to or lower than those of linezolid. Vancomycin and quinupristin-dalfopristin were also very active.
Hoellman
Dianne B
DB
Department of Pathology, Hershey Medical Center, Pennsylvania 17033, USA.
Lin
Gengrong
G
Ednie
Lois M
LM
Rattan
Ashok
A
Jacobs
Michael R
MR
Appelbaum
Peter C
PC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003470:Culture Media; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D010080:Oxazoles / Q000494:pharmacology*; D011008:Pneumococcal Infections / Q000382:microbiology; D013203:Staphylococcal Infections / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D003470:Culture Media; D005663:Furans; D010080:Oxazoles; C476340:ranbezolid